Poly(anhydride) nanoparticles containing cashew nut proteins can induce a strong Th1 and Treg immune response after oral administration

Pereira, Marcela Araújo; Rebouças, Juliana de Souza; Carvalho, Rafaela de Siqueira Ferraz; Redín, Inés Luis de; Guerra, Priscila Valera; Gamazo, Carlos; Brodskyn, Cláudia; Irache, Juan M.; Santos-Magalhães, Nereide Stela

doi:10.1016/j.ejpb.2018.02.011

Cited by 17 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More interestingly, cashew immunotherapy was also able to afford protection against other cross‐reactive tree nuts such as pistachio and walnut. More recently, Pereira et al evaluated the immunogenicity of orally administered poly(anhydride) nanoparticles loaded with cashew allergens in BALB/c mice 17 . These authors showed that nanoparticles were able to promote a strong specific Th1 response to cashew in association with an induction of FoxP3 + and LAP + T regulatory cells (T‐Reg).…”

Section: Discussionmentioning

confidence: 99%

Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis

Pelletier

Perrin

Assoun

et al. 2020

Allergy

View full text Add to dashboard Cite

Background The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. Objective We aimed to evaluate the capacity of EPIT to provide protection against cashew‐induced anaphylaxis in a relevant mouse model. Methods The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew‐sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast‐cell proteases (mMCP)‐1/7, were quantified. Results Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast‐cell reactivity as attested by the reduction of mMCP‐1/7 in plasma, suggesting that EPIT specifically decrease IgE‐mediated anaphylaxis. Conclusion We demonstrate that EPIT markedly reduced IgE‐mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy.

show abstract

Section: Discussionmentioning

confidence: 99%

Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis

Pelletier

Perrin

Assoun

et al. 2020

Allergy

View full text Add to dashboard Cite

show abstract

“…Other nanostructures of different chemical compositions, such as poly (anhydride) nanoparticles, have been studied in nut allergy. In fact, the poly (anhydride) nanoparticles containing nut proteins could induce a strong Th1 and Treg immune response after oral administration in a murine model of fatal anaphylaxis [ 111 , 112 , 113 ]. In addition, mannosylated nanoparticles for OIT in a murine model of peanut allergy showed both less serious anaphylaxis symptoms and higher survival rates than the control group, confirming the protective effect of this formulation against the challenge [ 114 ].…”

Section: New Therapeutic Approachesmentioning

confidence: 99%

New Insights in Therapy for Food Allergy

Mayorga

Palomares

Cañas

et al. 2021

Foods

View full text Add to dashboard Cite

Food allergy is an increasing problem worldwide, with strict avoidance being classically the only available reliable treatment. The main objective of this review is to cover the latest information about the tools available for the diagnosis and treatment of food allergies. In recent years, many efforts have been made to better understand the humoral and cellular mechanisms involved in food allergy and to improve the strategies for diagnosis and treatment. This review illustrates IgE-mediated food hypersensitivity and provides a current description of the diagnostic strategies and advances in different treatments. Specific immunotherapy, including different routes of administration and new therapeutic approaches, such as hypoallergens and nanoparticles, are discussed in detail. Other treatments, such as biologics and microbiota, are also described. Therefore, we conclude that although important efforts have been made in improving therapies for food allergies, including innovative approaches mainly focusing on efficacy and safety, there is an urgent need to develop a set of basic and clinical results to help in the diagnosis and treatment of food allergies.

show abstract

“…Particles made of amphiphilic polyanhydrides are biodegradable and show a favorable safety profile. Poly[methyl vinyl ether-co-maleic anhydride] (Gantrez® AN 119) has been investigated in mouse models for oral immunotherapy against peanut allergy ( 18 – 20 ), cashew nut allergy ( 21 ), and Lolium perenne pollen allergy ( 22 ). Three doses of nanoparticle-coated peanut allergens were able of protecting CD1 mice against severe anaphylaxis induced by a peanut challenge ( 18 ).…”

Section: Formulations With Vehicles That Protect Immunogenicitymentioning

confidence: 99%

“…Similar results were seen with allergens of L. perenne combined with Gantrez nanoparticles and LPS of Brucella ovis ( 22 ). Oral administration of cashew nut-loaded nanoparticles to BALB/c mice led to a decrease in splenic Th2 cytokines, and an enhancement of pro-Th1 and regulatory cytokines with an increased expansion of T regulatory cells compared to mice immunized with free allergens ( 21 ). Despite promising results in these murine models, no published studies in human or veterinary patients exist.…”

Section: Formulations With Vehicles That Protect Immunogenicitymentioning

confidence: 99%

Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon

Pali‐Schöll

DeBoer

Alessandri³

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Allergen immunotherapy is currently the only causal treatment for allergic diseases in human beings and animals. It aims to redirect the immune system into a tolerogenic or desensitized state. Requirements include clinical efficacy, safety, and schedules optimizing patient or owner compliance. To achieve these goals, specific allergens can be formulated with adjuvants that prolong tissue deposition and support uptake by antigen presenting cells, and/or provide a beneficial immunomodulatory action. Here, we depict adjuvant formulations being investigated for human and veterinary allergen immunotherapy.

show abstract

Poly(anhydride) nanoparticles containing cashew nut proteins can induce a strong Th1 and Treg immune response after oral administration

Cited by 17 publications

References 41 publications

Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis

Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis

New Insights in Therapy for Food Allergy

Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon

Contact Info

Product

Resources

About